Kitchen is empty currently.
Aurrigo International 125p £52.1m (AURR.L)
The international provider of transport technology solution reports its interim results for the six months to 30 June 2023. Revenue was up 35% to £3.1m (H1 22: £2.3m), the adjusted EBITDA loss was £1.6m (H1 22 loss: £0.3m), reflecting the scale up of the autonomous and aviation division. The cash was £2.8m at the period end. A European Institute of Innovation and Technology grant of €275k for a project to deploy the Auto-Shuttle in Prague was announced in September 2023. The Company has completed the extended development of Auto-DollyTug mk3 which will be delivered to market during 2023.
Caspian Sunrise 3.05p £66.4m (CASP.L)
The UK-based oil and gas exploration and production company announced its interim results for the six months ended 30 June 2023. Total revenue was $17.3m, down 32% (1H22: $25.6m), including revenue from oil production of $12.5m (1H22: $24.4m). The profit after tax was $7.5m (1H22: $7.3m), thanks to a significantly reduced tax charge. While the international oil price is strong and looks set to remain so in the foreseeable future, the Company continues for Russian sanctions related reasons to sell at domestic / local mini refinery prices, which have changed little since the end of the period under review. The immediate focus is on increasing production, principally from the MJF structure.
Coro Energy 0.29p £8.3m (CORO.L)
The South East Asian energy company with a natural gas and clean energy portfolio announces its unaudited interim results for the six-month period ended 30 June 2023. The reduced loss after tax from continuing operations of $2.5m (restated H1 2022: $3.8m) was mainly due to a reduction in net finance expense. Coro has a strong funding position from a combination of its cash balance of approximately US$0.7m (as at 30 June 2023), and more recently supported by the post balance sheet events of the sale of shares in ion Ventures Holding Ltd and a further advance of Italy sale proceeds.
Getech Group 7.6p £5.1m (GTC.L)
The locator of subsurface resources announces its unaudited interim results for the six months to 30 June 2023. H1 2023 revenues were £1.9m (H1 2022: £2.7m including a one-off £0.7m transfer payment), reflecting lower sales volumes in oil and gas. The orderbook value was £4.4m (30 June 2022: £4.8m) with £1.4m expected to convert in H2 2023, and a further £1.5m due in 2024. The cash balance was £2.0m at 30 June 2023 (31 December 2022: £4.3m). The proposed sale of Kitson House is progressing.
Helium One Global 6.35p £59.8m (HE1.L)
The primary helium explorer in Tanzania announces that the Tai-3 well commenced drilling on 25 September 2023, expecting to reach a total depth (TD) of approximately 1,100m two weeks from spud. The drilling is targeting multiple reservoir targets in the Lake Bed Formation, the Karoo Group and Basement. Baker Hughes wireline equipment and personnel are onsite to test equipment ahead of running wireline once TD has been reached. The whole process from spud to completion of logs and initial analyses is expected to take approximately four weeks.
Invinity Energy Systems 50p £95.5m (IES.L)
The global manufacturer of utility-grade non-lithium energy storage announces its unaudited results for the six months ended 30 June 2023. The Company reported £14.8m in total (including sales revenue and project-related grant income), a 10x increase year-on-year (H1 2022: £1.5m). The gross loss was £3.3m, reflecting previously disclosed and accounted for contract losses on Canadian and Australian projects (H1 2022: loss £2.1m). The loss from operating activities was £12.6m (H1 2022 loss: £12.1m). The period-end cash position was £12.9m (H1 2022: £16.1m).
Ondine Biomedical 9.25p £18.0m (OBI.L)
The Canadian life sciences company developing non-antibiotic photodisinfection therapies to prevent and treat healthcare-associated and drug-resistant infections announces its unaudited results for the six months ended 30 June 2023. Revenues were $0.43m, up 63% (H1 2022: $0.26m), reflecting the additional hospital clinical deployments. The loss from operations was $8.03m (H1 2022: $8.41m), largely due to the costs associated with clinical and regulatory efforts for the US market, public company-related costs, and expanding commercialisation reach. Cash, cash equivalents and restricted cash were $4.59m as at 30 June 2023 (31 December 2022: $13.27m). The Company is in discussions with the FDA on its Phase 3 protocol, and is coordinating the site and other details with its partner HCA Healthcare.
Saietta Group 38p £39.1m (SED.L)
The electric vehicle drivetrain (eDrive) specialist provides a trading update ahead of its AGM to be held on 26 September 2023. Turnover (sales and grant income) increased 40% to £6.0m (2022: £4.3m). The statutory loss before tax was £23.8m (2022: £11.3m) accounting for all write downs and discontinued activities. Cash as at 31 March 2023 period end was £7.3m (2022: £18.4m) and at end of August 2023 was £1.2m. With the cash resources and additional sums receivable from key customers and JV partners, the Board is confident that the Company has sufficient funding to meet its current requirements for the AFT eDrive production plan.
Spectra Systems 165p £74.8m (SPSY.L)
The leader in machine-readable high speed banknote authentication, brand protection technologies and gaming security software announces its interim results for the six months ended 30 June 2023. Revenue was $11.6m (1H22: $9.3m) up 25%. The increased revenues are derived principally from pre-production development contracts as well as larger demand for banknotes. Adjusted EBITDA was up 55% to $5.9m (1H22: $3.8m). The Company has a strong, debt-free balance sheet, with cash of $16.6m at 30 June 2023. The Company is on track to achieve record earnings and meet market expectations for the full year.
Transense Technologies 106.5p £16.5m (TRT.L)
The provider of specialist sensor systems announces its final results for the year ended 30 June 2023. Revenue was up 34% to £3.53m (FY22: £2.63m), and adjusted profit before taxation was £1.09m (FY22: £0.27m). Cash and cash equivalents at the year end was £0.98m (FY22: £1.06m). During the year, the Company completed share buybacks of £0.40m (FY22: £0.30m). The Company has achieved the strategic objectives set out in 2020, and now sets out commercial and financial goals for the medium term to 2028.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
